Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for HIND.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 -0.003M
March 31, 2026 5.289M
December 31, 2025 0.764M
September 30, 2025 -2.157M
June 30, 2025 0.6313M
March 31, 2025 0.16M
December 31, 2024 0.0535M
September 30, 2024 0.6205M
June 30, 2024 0.024M
March 31, 2024 0.00
December 31, 2023 5.461M
September 30, 2023 -0.338M
June 30, 2023 2.25M
March 31, 2023 10.20M
December 31, 2022 0.638M
September 30, 2022 0.003M
June 30, 2022 2.489M
March 31, 2022 0.00
December 31, 2021 0.00
September 30, 2021 -3.033M
Date Value
June 30, 2021 35.33M
March 31, 2021 1.00M
December 31, 2020 5.069M
September 30, 2020 1.50M
June 30, 2020 4.506M
March 31, 2020 0.00
December 31, 2019 -0.296M
September 30, 2019 9.88M
June 30, 2019 -6.814M
March 31, 2019 10.61M
December 31, 2018 -0.135M
September 30, 2018 9.95M
June 30, 2018 0.151M
March 31, 2018 0.028M
December 31, 2017 0.357M
September 30, 2017 0.009M
June 30, 2017 0.247M
March 31, 2017 0.00
December 31, 2016 67.22M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Cardiac Biotech Solutions, Inc. 0.19M
Anika Therapeutics, Inc. -0.701M
Enovis Corp. -50.56M
Edwards Lifesciences Corp. -0.30M
Perspective Therapeutics, Inc. 0.147M